L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
D000284:Administration, Oral; D000368:Aged; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D003248:Constipation / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D011792:Quebec; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine